Literature DB >> 10334492

A case history of glioma progression.

H Ohgaki1, K Watanabe, A Peraud, W Biernat, A von Deimling, M G Yasargil, Y Yonekawa, P Kleihues.   

Abstract

Low-grade diffuse astrocytomas have an intrinsic tendency for malignant progression but the factors determining the kinetics of this process are still poorly understood. We report here the case of a male patient who developed a fibrillary astrocytoma at the age of 33 years and who underwent six surgical interventions over a period of 17 years without radiotherapy or chemotherapy. The first three biopsies spanned a period of 11 years and led to the diagnosis of low-grade, diffuse astrocytoma (WHO grade II), with a growth fraction (MIB-1 labeling index) of 2.3-3.7%. The fourth to sixth biopsies showed histological features of anaplastic astrocytoma (WHO grade III), with growth fractions between 5.0 and 10.5%. The fraction of gemistocytic neoplastic astrocytes also increased, from 0.3% in the first biopsy to 17.5% in the last biopsy and preceded the increase in proliferative activity and transition to anaplastic astrocytoma. The fraction of tumor cells immunoreactive to BCL-2 increased from 0.3% to 8.2%. A p53 mutation in codon 273 (CGT-->TGT, Arg-->Cys) was identified in the first biopsy and persisted throughout the course of the disease. However, the fraction of cells with p53 protein accumulation increased significantly during progression, from 3.2% in the first biopsy to 13.7% in the last. The absence of additional genetic alterations (PTEN mutations, loss of chromosome 10 and 19q) may be responsible for the slow progression and lack of glioblastoma features even after a 17-year disease duration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334492     DOI: 10.1007/s004010051024

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  5 in total

Review 1.  Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma.

Authors:  Jason T Huse; Eric C Holland
Journal:  Nat Rev Cancer       Date:  2010-05       Impact factor: 60.716

Review 2.  Glioblastoma multiforme with an abscess: case report and literature review.

Authors:  Ondrej Kalita; Miroslav Kala; Hana Svebisova; Jiri Ehrmann; Alice Hlobilkova; Radek Trojanec; Marian Hajduch; Michael Houdek
Journal:  J Neurooncol       Date:  2008-06       Impact factor: 4.130

3.  Treatment of glioblastoma with herbal medicines.

Authors:  Ivo Trogrlić; Dragan Trogrlić; Darko Trogrlić; Amina Kadrić Trogrlić
Journal:  World J Surg Oncol       Date:  2018-02-13       Impact factor: 2.754

4.  TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT.

Authors:  Ivo Trogrlić; Dragan Trogrlić; Zoran Trogrlić
Journal:  Afr J Tradit Complement Altern Med       Date:  2016-09-29

5.  Systematic identification of lncRNA-based prognostic biomarkers for glioblastoma.

Authors:  Mingdong Li; Shengrong Long; Jinqu Hu; Zan Wang; Chao Geng; Shaowu Ou
Journal:  Aging (Albany NY)       Date:  2019-11-06       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.